Literature DB >> 22460735

Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia.

M Sivina1, E Hartmann, E Vasyutina, J M Boucas, A Breuer, M J Keating, W G Wierda, A Rosenwald, M Herling, J A Burger.   

Abstract

The tissue microenvironment in chronic lymphocytic leukemia (CLL) has an increasingly recognized role in disease progression, but the molecular mechanisms of cross talk between CLL cells and their microenvironment remain incompletely defined. Bone marrow stromal cells (BMSC) protect CLL cells from apoptosis in a contact-dependent fashion, and have been used for the identification of key pathways such as the CXCR4-CXCL12 axis. To further dissect the molecular impact of BMSC on survival and the molecular activation signature of CLL cells, we co-cultured CLL cells with different BMSC. Gene expression profiling of CLL cells revealed that the lymphoid proto-oncogene TCL1 was among the top genes upregulated in CLL cells by BMSC. TCL1 mRNA and protein upregulation by BMSC was paralleled by decreases of TCL1-interacting FOS/JUN, and confirmed by qRT-PCR, immunoblotting, immunoprecipitations, and flow cytometry. Stroma mediated increases in TCL1 were also associated with decreased levels of TCL1-regulatory micro-RNAs (miR-29b, miR-181b, miR-34b). These findings demonstrate that the microenvironment has a proactive role in the regulation of the known signaling enhancer and pro-survival molecule TCL1 in CLL. This provides a further rationale for therapeutically targeting the cross talk between CLL and BMSC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22460735     DOI: 10.1038/leu.2012.63

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  21 in total

1.  The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL.

Authors:  E Vasyutina; J M Boucas; J Bloehdorn; C Aszyk; G Crispatzu; M Stiefelhagen; A Breuer; P Mayer; C Lengerke; H Döhner; D Beutner; A Rosenwald; S Stilgenbauer; M Hallek; A Benner; M Herling
Journal:  Leukemia       Date:  2015-05-04       Impact factor: 11.528

2.  TCL1A and ATM are co-expressed in chronic lymphocytic leukemia cells without deletion of 11q.

Authors:  Angela Garding; Nupur Bhattacharya; Sarah Haebe; Frederike Müller; Dieter Weichenhan; Irina Idler; Katja Ickstadt; Stephan Stilgenbauer; Daniel Mertens
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

3.  Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL.

Authors:  Deyan Yordanov Yosifov; Irina Idler; Nupur Bhattacharya; Michaela Reichenzeller; Viola Close; Daria Ezerina; Annika Scheffold; Billy Michael Chelliah Jebaraj; Sabrina Kugler; Johannes Bloehdorn; Jasmin Bahlo; Sandra Robrecht; Barbara Eichhorst; Kirsten Fischer; Anja Weigel; Hauke Busch; Peter Lichter; Hartmut Döhner; Tobias P Dick; Stephan Stilgenbauer; Daniel Mertens
Journal:  Leukemia       Date:  2019-07-12       Impact factor: 11.528

4.  Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia.

Authors:  Warren Fiskus; Nakhle Saba; Min Shen; Mondana Ghias; Jinyun Liu; Soumyasri Das Gupta; Lata Chauhan; Rekha Rao; Sumedha Gunewardena; Kevin Schorno; Christopher P Austin; Kami Maddocks; John Byrd; Ari Melnick; Peng Huang; Adrian Wiestner; Kapil N Bhalla
Journal:  Cancer Res       Date:  2014-03-05       Impact factor: 12.701

Review 5.  Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling.

Authors:  Jan A Burger; Emili Montserrat
Journal:  Blood       Date:  2012-12-20       Impact factor: 22.113

Review 6.  Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade.

Authors:  Sarah E M Herman; Adrian Wiestner
Journal:  Semin Oncol       Date:  2016-02-08       Impact factor: 4.929

7.  miR-181b as a key regulator of the oncogenic process and its clinical implications in cancer (Review).

Authors:  Juan Liu; Weifeng Shi; Changping Wu; Jingfang Ju; Jingting Jiang
Journal:  Biomed Rep       Date:  2013-11-07

8.  Clustering of Expression Data in Chronic Lymphocytic Leukemia Reveals New Molecular Subdivisions.

Authors:  Sally Yepes; Maria Mercedes Torres; Rafael E Andrade
Journal:  PLoS One       Date:  2015-09-10       Impact factor: 3.240

9.  Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden.

Authors:  Christian Prinz; Elena Vasyutina; Gregor Lohmann; Alexandra Schrader; Steffen Romanski; Christoph Hirschhäuser; Petra Mayer; Corazon Frias; Carmen D Herling; Michael Hallek; Hans-Günther Schmalz; Aram Prokop; Dimitrios Mougiakakos; Marco Herling
Journal:  Mol Cancer       Date:  2015-06-04       Impact factor: 27.401

10.  Prognostic role of microRNA-181a/b in hematological malignancies: a meta-analysis.

Authors:  Shenglong Lin; Lili Pan; Shicheng Guo; Junjie Wu; Li Jin; Jiu-Cun Wang; Shaoyuan Wang
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.